We have previously developed and characterized a monoclonal anti-idiotype antibody, designated 6B11, which mimics an ovarian carcinoma associated antigen OC166-9 and whose corresponding monoclonal antibody is COC166-9 (Ab1). In this study, we evaluate the humoral immune responses induced by the fusion protein 6B11 single-chain variable fragment (scFv)/human granulocyte macrophage colony-stimulating factor (hGM-CSF) and 6B11scFv in BALB/c mice. Methods The fusion protein 6B11scFv/hGM-CSF was constructed by fusing a recombinant single-chain variable fragment of 6B11scFv to GM-CSF. BALB/c mice were administrated by 6B11scFv/hGM-CSF and 6B11scFv, respectively. Results The fusion protein 6B11scFv/hGM-CSF retained binding to the anti-mouse F(ab) 2 ' and was also biologically active as measured by proliferation of human GM-CSF dependent cell TF1 in vitro. After immunization with the 6B11scFv/hGM-CSF and 6B11ScFv, BALB/c mice showed significantly enhanced Ab3 antibody responses to 6B11scFv/hGM-CSF compared with the 6B11scFv alone. The level of Ab3 was the highest after the first week and maintained for five weeks after the last immunization. Another booster was given when the Ab3 titer descended, and it would reach to the high level in a week. Conclusion The fusion protein 6B11scFv/hGM-CSF can induce humoral immunity against ovarian carcinoma in vivo. We also provide the theoretical foundation for the application of the fusion protein 6B11scFv/hGM-CSF for active immunotherapy of ovarian cancer.
varian carcinoma associated antigen OC166-9 is recognized by a monoclonal antibody COC166-9 (Ab 1 ), which expressed in 75.6% of the epithelial ovarian carcinoma. 1 We have developed a murine monoclonal anti-idiotype (anti-Id) antibody, 6B11, which can mimic ovarian cancer associate antigen OC166-9 against anti-ovarian carcinoma monoclonal antibody COC166-9 for ovarian cancer immunotherapy. 2 Since 6B11 anti-Id antibody is murine derived, the efficacy of 6B11 as a tumor vaccine was evaluated in xenografts of nude mice tumor model, 3 Intact murine antibody can induce human anti-mouse antibodies (HAMA) in cancer patients receiving therapeutic monoclonal anti-Id antibody. 4 To overcome this limitation it is necessary to reconstruct anti-Id antibody. A first important step was cloning and engineering of anti-Id antibody heavy and light chain variable domains into single-chain variable fragments (scFvs, molecular weight about 28 kD), called 6B11scFv, 5 in which the variable regions are joined via a synthetic linker peptide sequence. Although scFvs themselves show limited tumor uptake in preclinical and clinical studies, they provide a useful building block for intermediatesized recombinant fragments.
The application of intact antibody molecules (about 150 kD) as therapeutic or diagnostic molecules remains limited due to their size, as they have limited tumor penetration and are cleared relatively slowly from the circulation resulting in low uptake ratio of tumor to blood. Monoclonal antibodies (mAbs) can be tailored to carry radionuclides, toxins, human IgG Fc domain or drugs for specific delivery to tumor cells. To improve the efficacy of the anti-tumor immune response, antibodies have been fused to cytokines or growth factors including interleukin (IL-2, IL-6) and granulocyte macrophage colony-stimulating factor (GM-CSF). [6] [7] [8] [9] [10] [11] The development of recombinant DNA techniques has enabled production of antibody fragments of various sizes and avidities and in vivo evaluation in tumor xenografts models. Also, recombinant antibody fragments have been generated exhibiting high tumor retention and fast blood clearance. These are desirable properties for imaging that result in high tumor to blood ratios in mice bearing human tumor xenograft. 7 Anti-Id antibodies offer many potential advantages in the therapy of carcinoma. Clinical studies have shown the induction of TAA-specific antibody (Ab3) responses by anti-Id antibody in tumor patients bearing a variety of tumor. [12] [13] [14] [15] GM-CSF is an immunoregulatory cytokine that induces the growth of granulocyte and monocyte progenitors and possesses important functions in the differentiation and maturation of hematopoietic cells, up-regulates class II MHC molecules, 12 and enhances their phagocytic activity and antigenpresenting capabilities. 16 GM-CSF stimulates the proliferation and survival of langerhans cells and dendritic cells in vitro, 17 and has been postulated to be a critical mediator in the primary immune response because of its action on these and other antigen presenting cells. 15 In vitro and in vivo studies have shown that GM-CSF fused to antibody molecules retains its biological activity and continues to mediate both antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
In the present study, we report the design of the scFv fusion protein 6B11scFv/hGM-CSF by genetic engineering and characterize its capability to elicit a specific humoral anti-ovarian carcinoma response (Ab3 response) in BALB/c mice. We also show Ab3 antibodies generated by vaccination with 6B11 intact antibody, 6B11scFv/hGM-CSF and 6B11scFv, respectively.
METHODS

Antigens and antibodies
Ovarian carcinoma associated antigen OC166-9 and corresponding monoclonal antibody COC166-9 (Ab1), 6B11 anti-idiotypic antibody mouse derived (Ab2) were prepared by Gynecologic Oncology Center, Peking University People's Hospital (Beijing, China).
Bacterial expression and preparation of protein fractions
The pET30a(+) 6B11scFv encoding 6B11scFv gene, pET30a(+) 6B11scFv/hGM-CSF encoding 6B11scFv gene and human GM-CSF gene were transformed into the E. coli strain BL21(DE3) (Invitrogen, USA) as expression hosts, respectively. Bacterial were grown in Luria-Bertani medium with 100 μg/ml kanamycin (Dingguo Company, Beijing, China) to an absorbance of 0.8 ( λ =600 nm). Then, isopropyl-Lthio-B-D-galacotpyranoside (Sigma-Jingmei, Beijing, China) was added to a final concentration of 0.4 mmol/L and incubation was continued at 37 o C for additional 4 hours. Subsequently, the cells were centrifuged (12 000×g, 4 o C, 20 minutes), and the pellet was resuspended in 50 mmol/L Tris-HCl (pH 8.0), 2 mmol/L EDTA, 0.35 mmol/L lysozyme (Sigma-Jingmei, Beijing, China), and 0.1% Triton X-100 for 15 minutes at 25 o C.
The cells were then cooled on ice, disrupted by ultrasound, and centrifuged (12 000 ×g, 4 o C, 20 minutes). Aliquots of three the soluble and the insoluble protein fraction were subjected to sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot analysis. The yield of recombinant proteins per milligram wet weight of the crude bacterial extract was assessed semiquantitiatively in SDS-PAGE by comparing the intensities of stained fusion protein bands to known amounts of the benchmark molecular weight marker proteins (Dingguo-life technologies, Beijing, China).
Refolding and purification of the insoluble protein fractions
The insoluble inclusion bodies were extensively purified by eight cycles of washing with PBS and subsequent centrifugation. The insoluble protein fraction was then denatured in a buffer containing 8 mol/L urea at room temperature for 2 hours, then placed at 10 o C for 48 hours.
The above inclusions were combined by diluting each to 1 µmol/L into a buffer containing 100 mmol/L Tris-HCl, 2 mmol/L EDTA, pH 8.0, at 4 o C for 48 hours. The 6B11scFv and 6B11scFv/hGM-CSF were refolded by dilution and purified by three runs over a Superdex G200 (Pharmacia, Sweden) gel filtration column, respectively. Fractions were pooled and concentrated after each run. The purity of protein was above 90%. Concentrations were estimated by SDS-PAGE reducing on pre-cast 12% polyacrylamide Ready Gels (Bio-Rad Laboratories, USA) as described. The proteins were detected by Coomassie Brilliant Blue R-250 staining by comparison with dilutions of known molecular weight of marker proteins.
SDS-PAGE and Western blot analysis of recombinant proteins
We used mouse anti-human GM-CSF monoclonal antibody as Ab1, goat anti-mouse IgG (peroxidase-labeled) as Ab2, COC166-9 horseradish peroxidase (HPR)-labeled to probe Western blots of purity proteins of bacterial. Proteins were determined by Bio-Rad Protein assay using low molecular standard (HuaMei Company, China).
Protein concentrations were boiled in reducing Laemmli sample buffer for 5 minutes, the proteins were separated by SDS-PAGE (12%) and transferred onto nitrocellulose. After blocking for 1 hour in 10% skimmed milk-PBS, the membrane was stained with COC166-9 HPR-labeled (0.1 mg/ml) for 90 minutes after three washing in PBS containing 0.05% Tween 20 (PBST), then showed color by DAB (di-azo-aminobenzene).
Activity assay of 6B11scFv by direct enzyme-linked immunosorbent assay (ELISA)
HRP-labeled goat anti-mouse F(ab) 2 ' was purchased from JingMei Company (Sigma, Beijing. China). Wells of a 96-well plate (Nunc, Denmark) were coated with 6B11scFv solution, 6B11scFv/hGM-CSF (from double dilution 80 μg/ml to 0.625 μg/ml), sameness measure 6B11 intact anti-antibody as positive controls in NaCl solution overnight at 4 o C, the coated plates were washed 3 times with NaCl solution+0.1% Tween 20, and 1/5000 dilution of HRP-labelled goat anti-mouse F(ab) 2 ' were added. After incubated at 37˚C for 1 hour, the plate was washed 3 times with NaCl solution +0.1% Tween 20 and 100 µl of o-phenylenediamine (OPD, 0.5 mg/ml), 0.06% H 2 O 2 in 0.18 mol/L sodium phosphate, 3.6 mmol/L tri-sodium citrate buffer (pH 5.0) were added. After 15 minutes at 37 o C, the enzymatic reaction was stopped with 50 µl 2 mol/L H 2 SO 4 . Absorbance values were determined at 490 nm using an ELISA reader (Bio-Rad Model 550, USA).
Activity assay of 6B11scFv/hGM-CSF
The reconstructed human GM-CSF was purchased from R&D System, USA. To determine the biological activity of the growth factor part of the 6B11scFv/hGM-CSF fusion protein, we did a cell growth assay using GM-CSF-dependent TF1 cells (human GM-CSF dependent cell line TFI was donated by Professor SHEN Pei-fen in Academy of Military Medical Sciences, China). Before cell culture, the soluble 6B11scFv/hGM-CSF and 6B11scFv preparations were dialyzed against tissue culture medium for 12 hours. Briefly, TF1 cells were maintained in RPMI1640 supplemented with 10% fetal calf serum (FCS) and 2% glutamine (Sigma Jingmei, China). Human GM-CSF, 6B11scFv and 6B11scFv/hGM-CSF fusion protein were added to the cells at different concentrations and the cell culture was continued for 48 hours at 37 o C in 5% CO 2 , respectively. Thereafter, [methyl-3 H] thymidine (China Institute of Atomic Energy, Beijing, China) was added for another 12 hours of incubation, after which the TF1 cells were harvested using a Combi-12 cell harvester and transferred to a filter. Thymidine incorporation was determined using a liquid sintillation β counter 90. All measurements were done in triplicates.
Immunization studies
The experiment was approved by Institutional Review Board of Peking University, China. BALB/c mice, female, 6-8 weeks old, purchased from Peking Health Science Center, China. The animals were immunized three times. The first was initial immunization, the second and third were boosting immunization. We divided the mouse into four groups randomly, and each group contained 8-12 mice. The four groups were immunized with 6B11ScFv plus complete and incomplete Freund's adjuvant (CFA and IFA) (Sigma Company, USA), 6B11scFv/hGM-CSF, respectively. The intact 6B11 anti-idiotypic antibody of mouse and PBS were used as positive and negative control respectively.
Initial immunization
One hundred μg different antigens were injected in three points subcutaneously to all mice. Equal dose of antigens and CFA were injected in adjuvant groups. We collected blood samples from the tail veins of mice every week after injection. Serum anti-Id antibody (Ab3) was measured by indirect ELISA. The mean numbers of Ab3 in three mice were calculated.
The first boosting immunization
The first boosting immunization was done two weeks after the initial immunization. Fifty μg antigens were used in each group. Injection location was the same as that of initial immunization. Adjuvant groups received the same IFA as 6B11ScFv. Ab3 was measured every week after the immunization using the same method as for the initial immunity.
The second boosting immunization
Two weeks after the first boosting immunization, the mice received the second boosting immunization. The dose was 50 μg in each groups, soluble water agents were injected into peritoneal cavity. The mice blood were collected from mice tail every week for 10 weeks after initial immunization.
Last boosting
The dose was 50 μg per mouse.
Detection of specific humoral immune response (Ab3) with 6B11scFv and 6B11scFv/hGM-CSF fusion protein
At specific time after immunization, we obtained blood samples through tail from mice in each group, and separated the serum after the last immunization. The blood of mouce tail were store at -20 o C. By means of indirect ELISA, coated with 100 μl ovarian carcinoma antigen OC166-9 (2 μg/ml) per well and stored at 4 o C overnight; washed three times with PBS-T, incubated with antiserum (1:20 dilution) from each immunity group at 37 o C for 1 hour (positive control with mouse intact anti-idiotypic antibody, negative control with PBS) and washed with PBS-T for 3 times, then incubated with HRP labeled goat antimouse IgG (1:1000, Beijing Zhongshan Biological Technology Ltd, China) at 37 o C for 1 hour. After 3 washing cycles with PBS-T, OPD was used to visualize positive wells. The OPD reaction was finally stopped with 2 mol/L H 2 SO 4 , and the optical density (OD) of each well was then measured at 490 nm using a microplate reader.
Statistical analysis
The statistical analyses were done using two-sample comparisons with SPSS software package (version 10.0). A P value less than 0.05 was considered statistical significance.
RESULTS
Preparation of protein fractions
The recombinant proteins were found as insoluble bacterial inclusion bodies and were processed as described. 18 On Western blot, both 6B11scFv and 6B11scFv/hGM-CSF fusion protein can bing to a COC166-9 HRP-labeled ( Fig. 1 ).
Functional properties of 6B11scFv and 6B11scFv/hGM-CSF fusion protein
As shown in Fig. 2 , the immunologic capability to bind to HRP-labelled goat anti-mouse F(ab) 2 ' was shown for 6B11scFv and for 6B11scFv/hGM-CSF fusion protein, respectively. Under equimolar conditions of 10 μg/ml for 6B11scFv and 20 μg/ml for 6B11scFv/hGM-CSF, the average binding seemed slightly higher for 6B11scFv/hGM-CSF (1.25±0.056) than for 6B11scFv (1.2 ± 0.001); but showed no statistical significance (P=1.00). Any comparison for 6B11scFv/hGM-CSF (1.25±0.056) and 6B11scFv (1.21±0.001) than for PBS (0.037±0.07) negative control is of statistical significance (P=0.000).
6B11scFv/hGM-CSF exhibits human GM-CSF activity
We tested the human GM-CSF bioactivity of the 6B11scFv/hGM-CSF fusion protein using human GM-CSF-dependent TF1 cells compared with human GM-CSF as a positive control. As shown in Fig. 3 , the fusion protein sustained proliferation of TF1 cells in a dose-dependent manner. The half-maximal proliferation was achieved at a concentration of 3.8 μg/ml 6B11scFv/hGM-CSF. Human GM-CSF used in identical proteincon-centration as for the fusion protein 6B11scFv/hGM-CSF sustained a comparable proliferation of the TF1 cells. As expected, 6B11scFv alone had no effect in proliferation. This experiment clearly showed that the human GM-CSF fusion partner of 6B11scFv/hGM-CSF had retained growth factor properties to stimulate cell growth of factor-dependent cells.
Induction of specific humoral immunity (Ab3) with 6B11scFv and 6B11scFv/hGM-CSF fusion protein in BALB/c mice
To identify Ab3 characterization, mouse serum combined with ovarian carcinoma initial antigen OC166-9 and the combination abilities were compared in each group 2 weeks after initial immunization and 3 weeks after the first boosting immunization. We observed that serum in all groups except positive control did not interact with OC166-9 in 2 weeks after initial immunization. But in 3 weeks after the first boosting immunity, the Ab3 level in serum of fusion protein 6B11scFv/hGM-CSF group was higher than that of other groups except positive control group. In 3 weeks after the first boosting immunization, Ab3 level was compared among animals immunized with 6B11 intact antibody, 6B11scFv and 6B11scFv/hGM-CSF fusion protein.
The level of Ab3 did not change significantly in animal group immunized with 6B11 intact antibody and 6B11scFv/hGM-CSF fusion protein. They were higher than the 6B11ScFv group (Table) .
Titer of Ab3 versus duration after immunization with 6B11scFv and 6B11scFv/hGM-CSF fusion protein
Ab3 was detected when BALB/c mice were immunized by 6B11scFv and 6B11 scFv/hGM-CSF fusion protein, respectively. All mice developed Ab3 binding to initial antigen OC166-9. Serum from PBS immunized control mice did not react with these antigens. Development of the titer of Ab3 is shown in Fig. 4 . Ab3 reached the highest at the fifth week after initial vaccination with 6B11scFv/hGM-CSF fusion protein, and its titer was kept for about 6 weeks. Another booster was given when the Ab3 titer descended, and it would reach to a higher level in a week, respectively. The results showed that after last immunization with 6B11 intact antibody, the mice serum Ab3 levels were enhanced quickly, the levels of Ab3 was kept for 9 weeks Another booster was given when the Ab3 titer descended, it would also reach to a higher level in a week. The Ab3 of 6B11 and 6B11scFv/hGM-CSF induced was still higher 2 times than 6B11scFv.
DISCUSSION
We have previously developed and characterized a monoclonal anti-idiotype antibody, designated 6B11, which mimics an ovarian carcinoma associated antigen OC166-9 and whose corresponding monoclonal antibody is COC166-9 (Ab1). It can also induce anti-anti-Id antibody (Ab3) in animals that is Ab1-like in their binding specificity and idiotope expression, which means that anti-Id antibody 6B11may be a potential therapeutic reagent as a tumor vaccine. But as a foreign protein, intact murine anti-Id antibody may induce some side reactions and limit its use in human bodies.
Anti-Id antibody can be mimicking tumor associated (TAAs) antigen to elicit effective immune response that will be capable to eradicate tumor cells and prevent tumor recurrence. However, TAAs are self-antigens against which clinically relevant humoral or cellular immune responses are not easily achieved. In a series of studies of Wagner, [19] [20] [21] [22] anti-anti-Id antibodies (Ab3) that bind to both ACA125 (Ab2) and CA125(Ab1) were produced by application ACA125 to immune epithelial ovarian cancer or recurrences. A Phase I/IIb multicenter study was conducted to evaluate the safety and immunogenicity of the anti-idiotypic antibody vaccine ACA125 that functionally imitates the tumor antigen CA125 in 119 patients with advanced ovarian carcinoma. In 81 patients (68.1%), a specific anti-anti-idiotypic antibody (Ab3) response could be induced. Ab3-positive patients showed a significantly longer survival (median, 23.4 months; P < 0.0001) as compared with Ab3-negative patients (median, 4.9 months). 14 Clinical studies with anti-idiotype antibodies ACA125 have shown Ab3 immune responses but the benefit for the patients thus far has been limited. Similarly, we have observed specific responses following vaccination with the full murine anti-idiotypic mAb 6B11 in immunocompetent mice bearing human ovarian carcinoma. 4 Different immunostimulatory cytokines, growth factors, human IgG Fc, or co-stimulatory antigens have been used either after fusion or by co-administration with antigens or antibodies to improve immune responses. [6] [7] [8] [9] [10] [11] In order to reduce murine monoclonal anti-Id antibody anti-human, Wagner et al 23 generated a single-chain fragment (ScFv) composed of ACA125 heavy-and light-chain variable domains connected by a polypeptide linker as an alternative to the corresponding F(ab') 2 fragment. But the anti-idiotypic scFv ACA125 must add adjuvant in vivo, it alone can not improve the immunogenic features of the corresponding mAb.
Genetically engineered anti-Id antibody fragments have shown great promise for the therapy of ovarian carcinoma. Retaining the exquisite specificity of intact murine monoclonal anti-Id antibodies and smaller in molecular size, anti-Id antibody fragments display rapid tumor targeting and blood clearance, a more uniform distribution in the tumor, and present a lower potential to elicit an immune response.
We have chosen human GM-CSF as a fusion partner, because it effectively stimulates professional antigen presenting cells including dendritic cells. We speculated that the fusion protein of the 6B11 anti-idiotype with hGM-CSF would effectively "address" to the hGM-CSF receptor, thereby enhancing the contact of the internal image of the specific COC166-9 epitope to antigen presenting cells for an improved antigen presentation. Indeed, the protein efficiently stimulates growth of the follicular dendritic cell line TF1 ( Fig. 3 ) and achieves an effective anti-tumor response not seen with the anti-Id 6B11 alone (Fig. 4) .
In our previous animal experiments, mice were immunized with implanted sub-nephrocapsular hybridoma which produces intact antibody 6B11 (Ab2 β ) against ovarian carcinoma. The results showed that the activation of humoral and cellular immunity against tumor could be induced. 4 To decrease the immunogenicity of 6B11, our center successfully constructed anti-idiotypic single chain antibody 6B11 by mean of genetic engineering technology. 5 The study of the efficiency and mechanism of fusion protein as vaccine in vivo could not be conducted, which limited its research and clinic study. So, we have previously constructed a fusion protein 6B11scFv/mouseGM-CSF which is similar to fusion protein 6B11scFv/hGM-CSF and could be studied in vivo. Using genetic engineering and protein engineering techniques, we constructed the fusion protein 6B11scFv/mouseGM-CSF (6B11mGM) of ovarian cancer anti-idiotypic single chain antibody (6B11ScFv) and mouse GM-CSF. In our study, immunizing the BALB/C mouse three times with 6B11mGM without any carrier protein or adjuvant induced the number of CD4 + lymphocytes of mouse spleen to increase and that of CD8 + cell to slightly increase and maintain at the increased level. This result showed that fusion protein 6B11mGM might activate CD4 + T cells and activate cellular immunity. 8 The fusion protein 6B11scFv/hGM-CSF can induce specific humoral immunity. Many studies showed that specific humoral immunity induced by anti-Id antibody (Ab2 β ) plays an important role in anti-tumor immunization. Mittelman et al 24 treated patients with late stage melanoma with mouse anti-idiotypic antibody mimicking melanoma associated antigen. Among the treated patients, 60% produced Ab3. There is significant association between Ab3 reactivity and the survival rate. Other researches also showed that Ab2 β can induce bodies to produce Ab3 to prolong survival and mediate a complement-dependent-(CDC) or an antibody-dependent cellular cytotoxicity (ADCC). 19 The study immunized BALB/c mice with ovarian cancer anti-idiotypic single chain antibody (6B11ScFv), intact antibody of 6B11 and 6B11scFv/hGM-CSF as antigens respectively. The results showed that the level of anti-idiotypic antibody Ab3 induced by 6B11scFv/hGM-CSF was much higher than that induced by 6B11ScFv. It suggests that the fusion protein 6B11scFv/hGM-CSF as vaccine without any carrying proteins or adjuvant could induce body to produce specific humoral immunity. By means of indirect ELISA to detect the level of Ab3 at different intervals (days), we found that the level of Ab3 was the highest on the first week and maintained for 5 weeks after the last immunization. Another booster was given when the Ab3 titer descended, and it would reach to a higher level in a week.
